The primary focus in the core is generating high-affinity monoclonal antibodies that are specific for the customers needs.Our scientist team also has expertise in more advanced techniques for antibody characterisation SPR, alternative antibody formats, humanisation and affinity maturation techniques.
ABN 12 377 614 012 Accessibility - Disclaimer and copyright - Website terms and conditions - Data Protection and Privacy Procedure - Data Consent Settings, Monash University CRICOS Provider Number: 00008C, Monash College CRICOS Provider Number: 01857J. Monash University is a registered higher education provider under the TEQSA Act 2011. Each profile provides a brief overview of the company, its contract service offerings, manufacturing capabilities and facilities and an informed future outlook. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies; recent approvals include (in reverse chronological order) Adakveo (November 2019), Beovu (October 2019), SKYRIZI (April 2019) and EVENITY (April 2019). Owing to their high specificity and the favorable safety profile associated with the therapeutic use of such molecules, antibody based interventions presently constitute the largest class of biologics in the industry. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragments-based products, are steadily gaining traction. Further, owing to legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements, outsourcing antibody production operations is a popular trend. Historical and prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. This dependence on outsourcing can be attributed to the high cost and time investment required to establish the necessary infrastructure and expertise in biologics. The competition among contract manufacturing organizations (CMOs) engaged in this domain is high, with the availability of cutting-edge tools and technologies being one of the key differentiating factors that grant a competitive advantage over other players. Therefore, in order to establish a strong foothold in the market and also meet the growing demand for antibody therapeutics reagents, CMOs are actively expanding their capacities and capabilities. Monoclonal Antibodies Production Facility Drivers And TrendsThe study also features a detailed analysis of key drivers and trends related to this evolving domain. Based on multiple parameters, such as projected growth of overall antibody-based products market, cost of goods sold and direct manufacturing costs, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth. Financial figures mentioned in this report are in USD, unless otherwise specified. It offers a high-level view on the current state of the antibody contract manufacturing market and its likely evolution in the short-mid term and long term. It highlights the different categories of antibodies, namely monoclonal antibodies, bispecific antibodies and polyclonal antibodies, their potential applications, and mechanisms of action (as therapeutic interventions). In addition, it includes information on the structure of an antibody and its isotypes. Further, the chapter features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the biopharmaceutical industry and its advantages. It includes information on over 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the CMO, number of manufacturing facilities, as well as location of these facilities, type of antibody manufactured, types of expression systems being used, fill finish operations and affiliations to regulatory agencies. The analysis compares companies on the basis of their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |